PTC596 in Patients With Advanced Solid Tumours

Official Title

A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumours

Summary:

This is a Phase 1, open-label, first-in-human, safety and pharmacokinetic study of PTC596 in patients with advanced cancer.

Trial Description

Primary Outcome:

  • Dose-limiting toxicities

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society